Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 5/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.47 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.44 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8029310 | 0.91 | CYSLTR1 (0.55) | CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL8029254 | 0.88 | GPBAR1 (0.53) | CYSLTR1CYSLTR2LTB4R | |
| SCHEMBL8029108 | 0.84 | CYSLTR1 (0.48) | CYSLTR1CYSLTR2LTB4R | |
| SCHEMBL9520446 | 0.81 | CYSLTR1 (0.54) | CYSLTR1CYSLTR2ALOX5APLTB4R | |
| SCHEMBL8030940 | 0.81 | ALOX5 (0.45) | CYSLTR1CYSLTR2LTB4R | |
| SCHEMBL8465764 | 0.80 | LTB4R (0.53) | CYSLTR1CYSLTR2LTB4R | |
| SCHEMBL8461585 | 0.78 | PDE10A (0.50) | CYSLTR1CYSLTR2ALOX5APLTB4R | |
| SCHEMBL8464766 | 0.78 | ALOX5AP (0.49) | CYSLTR1CYSLTR2ALOX5AP | |
| SCHEMBL8464764 | 0.78 | ALOX5AP (0.44) | CYSLTR1ALOX5AP | |
| SCHEMBL8034954 | 0.77 | ALOX5 (0.48) | CYSLTR1CYSLTR2LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6166031-A | Substituted tetralins, chromans and related compounds in the treatment of asthma | PFIZER INC, (US) | 2000-12-26 | — | — | US | disclosed |
| WO-1989003681-A1 | SUBSTITUTED TETRALINS, CHROMANS AND RELATED COMPOUNDS IN THE TREATMENT OF ASTHMA | PFIZER INC. (US) | 1989-05-05 | — | — | WO | disclosed |